SCHEMBL7119475

SCHEMBL7119475

CCOC(=O)c1ccc(Sc2ccccc2N)cc1C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.65
POLB P06746 2/20 0.65
MAPK1 P28482 1/20 0.65
HSD17B10 Q99714 5/20 0.52
TSHR P16473 2/20 0.48
MAPT P10636 5/20 0.43
HPGD P15428 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
KDM4E B2RXH2 3/20 0.41
CDC25B P30305 2/20 0.41
PKM P14618 1/20 0.41
NPC1 O15118 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
MCL1 Q07820 1/20 0.40
BCL2A1 Q16548 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7116623 0.82 LMNA (0.49) ALDH1A1POLBMAPK1HSD17B10TSHR
SCHEMBL7119473 0.79 ALDH1A1 (0.53) ALDH1A1POLBMAPK1HSD17B10TSHR
SCHEMBL9131623 0.79 ALDH1A1 (0.69) ALDH1A1POLBMAPK1HSD17B10TSHR
SCHEMBL7617766 0.78 ALDH1A1 (0.58) ALDH1A1POLBMAPK1HSD17B10TSHR
SCHEMBL7620547 0.77 ALDH1A1 (0.50) ALDH1A1POLBMAPK1HSD17B10TSHR
SCHEMBL1027580 0.76 ALDH1A1 (0.58) ALDH1A1POLBMAPK1HSD17B10TSHR
SCHEMBL7129352 0.75 ALDH1A1 (0.62) ALDH1A1POLBMAPK1HSD17B10TSHR
SCHEMBL1403646 0.74 TSHR (0.55) ALDH1A1POLBMAPK1HSD17B10TSHR
Ethyl Anthranilate SCHEMBL27460908 0.74 ALDH1A1 (0.87) ALDH1A1POLBMAPK1HSD17B10TSHR
SCHEMBL7118376 0.74 ALDH1A1 (0.54) ALDH1A1POLBMAPK1HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics KRISTIANSEN MARIT (DK) 2003-10-02 US disclosed
US-6590118-B1 Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) NOVO NORDISK A/S (DK) 2003-07-08 US disclosed
EP-1220832-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2002-07-10 EP disclosed
WO-2001023347-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics PYGL, GYS2, PYGM ALDH1A1 901/4885POLB 2900/4885MAPK1 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.